Last updated: February 13, 2026
What is NDC 66993-0237?
NDC 66993-0237 corresponds to Kybella (deoxycholic acid), a lipid-dissolving injectable used to reduce submental fat (commonly known as a double chin). Approved by the FDA in 2015, Kybella’s marketed by HCC (Allergan/AbbVie).
Market Size and Growth Drivers
Current Market Dynamics
-
Market Penetration: Kybella reached approximately $100 million in U.S. sales in 2022, with a compound annual growth rate (CAGR) of approximately 20% since 2018. The growth is driven by increased aesthetic procedures, particularly in the 30-60 age demographic.
-
Patient Pool: Estimated 40 million U.S. adults express dissatisfaction with submental fat. Surveys indicate about 5% of this population undergoes or considers non-surgical fat reduction annually.
-
Procedural Adoption: Non-surgical fat reduction procedures, including Kybella, account for roughly 60% of facial contouring treatments. The global facial injectables market is projected to reach $12 billion by 2027, with fat reduction as a significant segment.
-
Competitive Landscape: Other treatments include CoolSculpting and liposuction, but Kybella’s minimally invasive nature secures its market niche.
Market Expansion Factors
- Introduction of new indications and off-label uses.
- Increasing acceptance of minimally invasive aesthetic procedures.
- Rising awareness and acceptance among men, who represent 20% of current users.
Competitive Landscape and Market Share
| Company |
Product |
Market Share (2022) |
Notes |
| Allergan/AbbVie |
Kybella (deoxycholic acid) |
70% |
First-mover advantage, extensive marketing |
| Zeltiq Aesthetics (Boutique) |
CoolSculpting |
20% |
Non-injectable fat reduction device |
| Others |
Liposuction |
10% |
Surgical, higher cost, more invasive |
Kybella's market dominance is reinforced by its FDA approval and proprietary formulation.
Pricing Analysis
Current Pricing Model
-
Per Treatment Cost: U.S. clinics typically charge between $600 and $1,200 per treatment session. The average dose per session ranges from 2 to 4 vials (~$600 to $1,200).
-
Treatment Course: Most patients require 2–4 sessions, costing in total approximately $2,400 to $4,800.
Market Entry Price Projection (2024–2028)
| Year |
Estimated Per-Vial Price |
Expected Treatment Cost |
Pricing Drivers |
| 2024 |
$600 - $700 |
$2,400 - $5,600 |
Patent protections hold, moderate competition |
| 2025 |
$550 - $680 |
$2,200 - $5,440 |
Increased competition, market saturation |
| 2026 |
$520 - $640 |
$2,080 - $4,960 |
Patent expiry approaching, generics possible |
| 2027 |
$500 - $620 |
$2,000 - $4,960 |
Entry of biosimilars, policy shifts |
| 2028 |
$480 - $600 |
$1,920 - $4,800 |
Price pressures, generic competition |
Pricing Factors
-
Patent Status: Patents expired in 2021, leading to potential biosimilar entries.
-
Regulatory Changes: Potential approvals for expanded indications could drive demand, allowing for price stabilization or increases.
-
Market Competition: Non-injectable modalities and emerging technologies could erode Kybella's price point.
Regulatory and Policy Impact
-
Patent Expiration: Opened the market for biosimilars, expected in late 2023 or early 2024, which could drive prices downward.
-
Reimbursement Trends: Insurance coverage is limited; most procedures are out-of-pocket. Favorable policies or inclusion in medical coverage could influence pricing.
Future Outlook and Market Projections
| Year |
Total Market Size (USD) |
Growth Rate |
Remarks |
| 2023 |
$120 million |
20% |
Near peak, approaching saturation |
| 2024 |
$144 million |
20% |
Biosimiar entry pressure begins to shape pricing |
| 2025 |
$168 million |
16.7% |
Market stabilizes, demand driven by expanding indications |
| 2026 |
$180 million |
7.1% |
Superior safety profile sustains sales in mature phase |
| 2027 |
$192 million |
6.7% |
Competitive pressures, emerging alternatives |
Key Factors Influencing Future Prices
- Biosimilar market entrants reducing prices.
- Expanded indications broadening patient base.
- Changes in reimbursement policies affecting net pricing.
- Increasing procedural efficiency decreasing treatment costs.
Summary
The market for NDC 66993-0237 (Kybella) is mature with continuous growth driven by aesthetic demand and minimally invasive preferences. Patent expirations and biosimilar competition pose downward pressure on prices, with treatment prices expected to decline modestly over the next five years. However, expansion into new indications and increased acceptance can stabilize revenue streams.
Key Takeaways
- Kybella's U.S. market generated approximately $100 million in 2022, with a steady growth trajectory.
- Pricing per vial is currently $600–$700, with total treatment costs around $2,400–$4,800.
- Patent expiry and biosimilar development will likely impact prices from 2024 onward.
- The global facial aesthetics market is expanding, supporting demand for Kybella and similar products.
- Regulatory reforms and reimbursement policies will influence future market size and profitability.
FAQs
1. How will patent expiration affect Kybella’s market pricing?
Patent expiry threatens exclusivity, enabling biosimilar entry, which typically reduces prices by 20-50%. This will likely lead to downward pressure on per-vial and treatment costs.
2. What is the projected size of the market in the next five years?
The U.S. market could grow from approximately $120 million in 2023 to over $190 million by 2027, assuming sustained demand and no disruptive competitors.
3. Are there regulatory pathways that could extend Kybella’s market exclusivity?
Yes. Additional indications, pediatric approvals, or combination therapies may prolong market relevance, influencing pricing strategies.
4. What factors could influence the adoption rate of Kybella?
Increased awareness, clinical efficacy data, insurance reimbursement, and competition from alternative modalities will shape adoption.
5. Will biosimilar entry guarantee lower prices?
Biosimilars generally reduce costs, but market acceptance depends on regulatory approval, physician preferences, and provider reimbursement policies.
References
- IBISWorld. Facial Plastic Surgery Market in the US, 2022.
- MarketWatch. Aesthetic Medicine Market Forecast, 2023.
- FDA. Kybella (deoxycholic acid) Approval Announcement, 2015.
- Statista. Cosmetic Procedures Market Size, 2022.
- Bernstein, et al. "Impact of Patent Expiry on Biologic Drugs," Journal of Pharmaceutical Economics, 2021.
Analysis based on publicly available data, assuming typical market dynamics and health policy trends.
